Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
TECENTRIQ (Roche Products Pty Ltd)
Product name
TECENTRIQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
196 working days (255)
Active ingredients
atezolizumab
Registration type
EOI
Indication
Non-small cell lung cancer
TECENTRIQ, in combination with bevacizumab, paclitaxel and carboplatin, is now also indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, TECENTRIQ, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
TECENTRIQ as monotherapy is now also indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.